Intellia Therapeutics price target lowered to $50 from $90 at Truist

Truist analyst Joon Lee lowered the firm’s price target on Intellia Therapeutics (NTLA) to $50 from $90 and keeps a Buy rating on the shares. Intellia’s restructuring should help extend the company’s operational runway into the first half of 2027, as NTLA-2002 is poised to be the historic first in vivo genome editing therapeutic to launch in 2027 for hereditary angioedema, the analyst tells investors in a research note. While the firm believes Intellia has a winning platform, it says it is headed in an increasingly competitive space, driving the firm to moderate its commercial outlook for nex-z in transthyretin amyloidosis.